Butterfly Medical, a medical device company focused on alleviating suffering in patients with BPH (Benign Prostatic Hyperplasia), has announced today the appointment of Dr James (Jim) Ulchaker as the company’s Chief Medical Officer.
Dr Ulchaker will focus on aligning Butterfly Medical’s novel BPH treatment with the medical needs of patients, while also contributing to the company’s medical safety, professional society alignment and product strategy as the company pursues FDA approval.
BPH affects up to 50 percent of men between the ages of 51 and 60, and more than 70 percent of men aged 60 to 69.
This non-cancerous prostate enlargement significantly impacts quality of life, causing symptoms including difficulty urinating, frequent urination and potential sexual dysfunction, while also affecting emotional wellbeing.
As the global population ages, the prevalence of BPH is rising, making it a growing challenge for healthcare systems worldwide.
Patrick MacCarthy, CEO of Butterfly Medical, said: “With the high prevalence of BPH and the increasing demand for treatment, developing a minimally invasive solution to address key clinical challenges has the potential to significantly improve patients’ quality of life.
“Dr Ulchaker’s urological expertise and dedication to advancing treatment options will help the company prepare to bring our BPH treatment to the U.S. market.”
With limited BPH treatment options available, Butterfly Medical has developed an implantable device that does not require cutting or removing tissue.
Clinical trials have shown that this procedure is minimally invasive, fully reversible, and effectively retracts the lateral lobes of the prostate without piercing or burning tissue.
The Butterfly Medical device has CE Mark Approval and is currently being evaluated in a pivotal clinical study in the U.S.
Dr Ulchake said: “The opportunity to contribute to the development of such an innovative treatment for BPH is extremely exciting.
“Butterfly Medical’s minimally invasive device is uniquely shaped to fit the anatomy of the prostatic urethra, dilating the obstructed area to restore urine flow and improve quality of life.
“It has the potential to provide a safe and effective new option for patients seeking relief, and I look forward to helping to bring the device to those who can truly benefit.”
